Answer
Vildagliptin inhibits DPP-4, increasing GLP-1 and GIP hormones to improve glucose-dependent insulin secretion and glucose-appropriate glucagon secretion, thereby reducing liver glucose production and blood glucose; it does not stimulate insulin secretion or lower glucose in people with normal blood glucose.
Sources for this answer
- Galvus 50 mg TabletsNovartis Pharmaceuticals UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 24Document updated
Sources checked